[G19-11] Cabozantinib (hepatocellular carcinoma) - Second Addendum to Commission A18-85
Last updated 06.06.2019
Project no.:
G19-11
Commission:
Commission awarded on 24.04.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A19-38 | Cabozantinib (hepatocellular carcinoma) - Addendum to Commission A18-85 | Commission completed |
| A18-85 | Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-06-06 A G-BA decision was published.